Clean Intermittent Self Catheterisation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Clean intermittent self-catheterisation (CISC), also known as clean intermittent catheterisation (CIC), is a technique in which the patient uses a catheter to drain the bladder completely at regular intervals throughout the day, then removes the catheter until the next scheduled emptying. Unlike an indwelling urethral catheter (Foley catheter), which remains in the bladder continuously, CISC is performed intermittently, typically 4–6 times per day, mimicking the natural filling and emptying cycle of the bladder.

CISC is the gold standard management for patients with impaired bladder emptying due to neurological conditions (neurogenic bladder), anatomical bladder outlet obstruction, detrusor underactivity, or post-surgical bladder dysfunction. It was pioneered in the 1970s by Lapides and colleagues, who demonstrated that aseptic technique was not necessary provided the catheter was clean and the procedure was performed regularly — the 'clean' rather than 'sterile' technique being the key insight that made home self-management feasible.

The technique involves using a single-use hydrophilic-coated catheter (pre-lubricated with water activation) or a reusable catheter (cleaned between uses), inserting it through the urethra into the bladder, draining the urine completely, and then withdrawing the catheter. A continence nurse specialist provides 1–3 teaching sessions to ensure competence, confidence, and understanding of technique. Most patients achieve independence with CISC within a few days of training. The technique is safe, effective, and well-tolerated when performed regularly and correctly.

Neurogenic bladder dysfunction is the most common indication for CISC. Conditions causing neurogenic bladder include multiple sclerosis (where bladder dysfunction affects up to 80% of patients), spinal cord injury (causing either upper or lower motor neurone bladder patterns requiring CISC), spina bifida, Parkinson's disease, diabetic autonomic neuropathy, and cauda equina syndrome. These conditions impair the neural control of the detrusor muscle and urethral sphincter, resulting in incomplete bladder emptying with residual urine volumes that predispose to recurrent urinary tract infections and upper tract damage.

Benign prostatic hyperplasia (BPH) causing chronic urinary retention with high residual volumes is an important indication for CISC in older men, particularly those awaiting transurethral resection of the prostate or in whom surgery is contraindicated. Post-operative bladder atony following pelvic surgery (hysterectomy, anterior resection, radical prostatectomy) commonly requires temporary CISC while bladder function recovers. Urethral stricture in men, where catheterisation is part of ongoing management, and detrusor underactivity (underactive bladder) causing incomplete emptying with overflow incontinence are further indications.

Any patient with incomplete bladder emptying (residual urine volume > 100–150 mL on bladder ultrasound scan or catheterisation) causing recurrent UTIs, urinary tract dilatation, or upper tract compromise is a candidate for CISC. The technique is suitable across a wide age range from children with spina bifida to elderly patients with diabetic neuropathy or BPH. Physical and cognitive requirements include: sufficient manual dexterity and coordination to insert the catheter, the ability to follow a schedule, and adequate cognition to understand the technique and the importance of regularity.

Contraindications are few: active urethral stricture too tight for catheter passage (requiring urological dilatation first), known urethral trauma, severe urethral anatomical abnormalities, and patients who are physically or cognitively unable to perform the technique without assistance (who may require assisted intermittent catheterisation by a carer). Patients with anticoagulation can safely perform CISC with adequate lubrication to minimise trauma. Women with obesity, limited limb mobility, or visual impairment may face technical challenges that can often be overcome with adaptive equipment such as catheter guides, leg abductors, or hand-held mirrors.

Single-use hydrophilic-coated catheters are now the standard of care in most countries. They are pre-coated with a hydrophilic polymer that becomes extremely lubricious when activated by immersion in water or by a water sachet within the catheter packaging, minimising urethral friction and trauma. Pre-lubricated gel-coated catheters (Nelaton design or coudé-tip for men with BPH or urethral angulation) are alternatives that do not require water activation and are convenient for travel.

Reusable catheters require washing with soap and water between uses and replacement every 5–7 days; they are the standard in countries where single-use catheters are not funded, but carry a slightly higher UTI risk and require more patient diligence. Catheter size (French/Charrière gauge) is selected by the continence nurse based on the patient's anatomy — typically 10–14 Fr for women and 12–16 Fr for men. The catheterisation schedule — typically every 3–4 hours when awake to maintain bladder volumes below 400 mL — is individualised based on fluid intake, bladder capacity, and leak assessment. Bladder management apps and bladder diaries help patients maintain appropriate schedules.

Individualised treatment planning is essential to achieve optimal outcomes. Factors including patient age, overall health status, concurrent medications, and personal goals all influence the selection and sequencing of treatment approaches. A specialist consultation — with review of relevant investigations and prior treatment history — is the appropriate first step before any therapeutic intervention is initiated. Patients are encouraged to seek a second opinion for complex or elective procedures to ensure they understand all available options and their respective risks, benefits, and costs.

CISC consistently reduces the rate of symptomatic urinary tract infections compared to indwelling urethral catheterisation, which carries a UTI rate of approximately 10% per catheter day. Studies comparing CISC with indwelling catheterisation show a 5–8-fold reduction in UTI rates in neurogenic bladder patients managed with CISC. Critically, CISC preserves upper urinary tract function (kidneys, ureters) by preventing bladder overdistension and the high intravesical pressures that cause vesicoureteric reflux and hydronephrosis.

Patients performing CISC regularly report significantly better quality of life, greater social independence, and reduced anxiety about incontinence compared to those with indwelling catheters. The technique allows full participation in work, travel, exercise, and intimate relationships in a way that indwelling catheterisation does not. Long-term renal function is better preserved in patients with neurogenic bladder who perform CISC consistently, representing one of the most important health benefits of the technique over a lifetime. Patient acceptance and long-term adherence are generally high — over 80% of patients initiated on CISC continue it long-term in published cohort studies.

Urinary tract infection is the most common complication of CISC, occurring in approximately 0.3–1.4 episodes per year in patients performing the technique correctly. Risk factors for UTI in CISC include poor technique, inadequate catheterisation frequency (residual urine volumes exceeding 400 mL), dehydration, and use of reusable catheters. Most UTIs are uncomplicated lower urinary tract infections treatable with a short course of antibiotics; asymptomatic bacteriuria (bacteria in the urine without symptoms) is common and does not require treatment.

Urethral trauma from incorrect catheter insertion, insufficient lubrication, or forcing the catheter past resistance can cause urethral bleeding, false passage creation, or urethral stricture over time. This underscores the importance of adequate initial training, use of well-lubricated catheters, and applying gentle sustained pressure without forcing at points of resistance. Epididymo-orchitis in men (infection ascending from the urethra) is a rare but serious complication. Bladder calculi (stones) can form around catheter fragments in patients using reusable catheters that are not replaced regularly. Haematuria following catheterisation is common (particularly after urethral trauma) and usually resolves without intervention.

After initiating CISC, patients are reviewed by the continence nurse at 1–2 weeks to assess technique, troubleshoot difficulties, review the catheter schedule based on bladder diary data, and address any concerns about UTI or urethral discomfort. A urine culture is typically sent at the initial review to exclude asymptomatic bacteriuria and establish a baseline. Follow-up with the urologist occurs at 3 months for formal urodynamic or ultrasound reassessment of residual urine volumes, bladder compliance, and upper tract status.

Long-term, patients require annual urological review including bladder ultrasound and renal function tests (eGFR, serum creatinine). Those with neurogenic bladder from spinal cord injury or spina bifida require regular videourodynamic studies (every 1–2 years) to monitor bladder compliance and protect upper tract function. Catheter prescriptions are reviewed annually to ensure the most appropriate catheter type and size is being used. Patients should seek urgent review for symptoms of UTI (fever, rigors, loin pain), haematuria, difficulty passing the catheter, or inability to drain urine.

In the UK, single-use hydrophilic catheters for CISC are available on NHS prescription at no cost to the patient. The annual cost to the NHS is approximately GBP 800–2,000 per patient depending on catheter type and frequency of use. In the US, single-use catheters cost USD 1–5 each; at 4–6 per day, annual catheter costs are USD 1,500–10,000 without insurance coverage. Medicare and Medicaid cover a limited monthly supply of intermittent catheters for patients meeting specific criteria.

In India, Thailand, and other medical tourism destinations, single-use hydrophilic catheters are available at significantly lower cost: USD 0.30–1.50 per catheter. Initial urological consultation and training for CISC at private hospitals in India costs USD 30–100. Patients seeking urological care abroad for neurogenic bladder assessment and CISC initiation can access world-class urodynamic testing and specialist continence nurse training at 60–75% lower cost than in the US or UK. Reusable catheters remain the primary option in many lower-income countries due to cost, with appropriate training in cleaning technique.

Indwelling urethral catheterisation (Foley catheter) and suprapubic catheterisation (catheter placed through the abdominal wall directly into the bladder) are alternatives for patients who are unable to perform CISC. However, indwelling catheters carry significantly higher risks of urinary tract infection, bladder stones, urethral erosion, and impaired quality of life, and are reserved for patients for whom CISC is truly not feasible. Suprapubic catheterisation is preferred over urethral indwelling catheters for long-term drainage in selected patients.

Surgical alternatives for specific underlying conditions may reduce or eliminate the need for CISC: transurethral resection of the prostate (TURP) for BPH, urethral dilatation or urethroplasty for stricture, and sacral neuromodulation or botulinum toxin injection for some forms of neurogenic bladder dysfunction. Penile compression devices are non-catheter alternatives for men with overflow incontinence from incomplete emptying, but do not address the risk of upper tract damage from high residual volumes. None of these alternatives is universally applicable — CISC remains the most versatile, physiological, and safest long-term management approach for most patients with significant chronic urinary retention.